Xenexus Pharmaceuticals is building a pipeline of small molecule therapeutics based on drug repurposing. They offer the prospect of multi-target drugs with broad applicability across a range of complex diseases. The portfolio includes the following projects.
XEN-101 is a treatment for nonalcoholic steatohepatitis.
XEN-102 is a treatment for Long COVID.
The company's strategy is to progress its drug candidates into early clinical trials and then to out license to a large pharmaceutical partner for onward development and commercialisation.